Esomeprazole Magnesium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Esomeprazole Magnesium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
704
Registered trials
116
Result records
19
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Esomeprazole Magnesium can convert its Small molecule drug profile and Proton pump biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Esomeprazole Magnesium (query alias: esomeprazole) |
|---|---|
| Modality / target | Small molecule drug; Proton pump; Proton pump inhibitors |
| Highest global status | Approved |
| Originator | AstraZeneca PLC |
| Active developers | AstraZeneca Pty Ltd., AstraZeneca Pharmaceuticals Co. Ltd., Azurity Pharmaceuticals, Inc. |
The MCP disease footprint includes Anastomotic ulcer, Esophagitis, Helicobacter pylori infection. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07574879 | Phase 1 | Recruiting | 54 | Primary outcome measures |
| NCT07563491 | Not Applicable | Completed | 824 | Sufficient relief |
| CTR20262545 | Not Applicable | 进行中 （尚未招募） | 104 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
An Open Label, Parallel Group, Multi-centre, Phase III Study to Assess the Efficacy and Safety of D961H for the Maintenance Therapy Following Initial Treatment in Japanese Paediatric Patients With Reflux Esophagitis and for the Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer in Japanese Paediatric Patients Treated With Non-steroidal Anti-inflammatory Drugs or Low-dose Aspirin
Phase 3; n=50; evaluation: not stated. Reported fields: -; -; -
A Phase I/II Study of Dermaprazole For Radiation Dermatitis in Post-Mastectomy Breast Cancer Patients.
Phase 1/2; n=3; evaluation: not stated. Reported fields: Number of Participants With Dose-Limiting Toxicity(DLT) in Phase I = 0 Participants ; -; -
Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based quadruple therapy for Helicobacter pylori eradication: A multicenter, double-blind, randomized, phase 3 study
Phase 3; n=510; evaluation: Positive. Reported fields: Eradication rate of H. pylori = 86.7 % ; Eradication rate of H. pylori = 86.8 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Esomeprazole Magnesium addresses Anastomotic ulcer, Esophagitis, Helicobacter pylori infection. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 19 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Proton pump records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-04-23 | Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals | Approved | Financial terms not disclosed |
| 2026-01-19 | Hyloris Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European Markets ENGLISH VERSION | Approved | Financial terms not disclosed |
| 2025-12-20 | Pfizer and Cipla announce partnership | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “A pharmaceutical composition comprising naproxen and esomeprazole”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition comprising esomeprazole and sodium bicarbonate having excellent release properties”. The milestone feed surfaced a patent-application signal described as “Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
